Loading company…
Pittsburgh-based LyGenesis develops cell therapies that use patients' lymph nodes to grow functioning organ tissue.
Founded in 2017 in Pittsburgh, US, LyGenesis Inc. is developing treatments for Type 1 diabetes and end-stage liver and renal disease. Its approach uses the patient's lymph nodes as bioreactors, and the outpatient procedure is performed via endoscopic ultrasound. Co-founded by Michael Hufford and Paulo Fontes, the company raised USD 8.731 mn in a Series A round led by Prime Movers Lab on October 5, 2023, with Juvenescence Therapeutics Limited participating. The round valued the company at USD 46.999 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in